Financial Data and Key Metrics Changes - Total net sales for Q4 2025 were $57.8 million, compared to $49 million in the same quarter last year, driven by a lower than expected rebound in sales in China, partially offset by growth in the Americas and non-China APAC regions [21] - Gross profit margin for Q4 2025 was 75.7%, up from 64.7% in the prior year quarter, primarily due to cost reductions and the ramp-up of Swiss manufacturing [22] - Adjusted EBITDA for Q4 2025 was a loss of $200,000, an improvement from a loss of $20.8 million in the year-ago quarter [24] Business Line Data and Key Metrics Changes - China net sales in Q4 2025 were $17.5 million, up from $7.8 million in the year-ago quarter, although certain sub-distributors returned inventory, impacting sales [21] - Excluding China, net sales declined by 2% year-over-year, with the Americas up 18%, EMEA down 20%, and APAC ex-China up 2% in Q4 [22] Market Data and Key Metrics Changes - In China, demand for EVO ICL recovered at mid-single digit rates, but did not translate into net sales growth due to inventory reductions by distributors [10] - The U.S. business showed momentum despite a decline in laser vision correction procedures, with an expanded age range indication for EVO increasing the potential candidate pool by approximately 8 million [11] Company Strategy and Development Direction - The company aims for growth, improving profitability, and progress across its innovation pipeline in 2026, following a challenging 2025 [8] - Focus on enterprise-wide impacts and disciplined investing to drive profitability, including manufacturing improvements and optimizing average selling prices (ASPs) [13] - The launch of EVO+ in China and the expansion of the LIOLI injector for EVO ICL procedures are key components of the growth strategy [14][15] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the recovery in China and the potential for growth in 2026, despite previous macroeconomic challenges [10] - The company is focused on restoring revenue and maintaining cost discipline, with a target for profitability in FY 2026 [25][26] - Management emphasized the importance of innovation and the need to bring new products to market to maintain competitive advantage [85] Other Important Information - The company has engaged a search firm to find a permanent CEO, indicating a focus on leadership stability during this transition [8] - The company has no debt and ended Q4 2025 with approximately $187.5 million in cash equivalents and investments [25] Q&A Session Summary Question: Have the reductions in distributor inventory continued into Q1? - Management confirmed that inventory levels are stable and below contractual levels, indicating readiness for market recovery [32] Question: How does the health of the organization compare to pre-Alcon? - Management noted that expenses have been controlled since Q1 2025, and the organization is aligned around growth and profitability goals [36] Question: What is the expected growth for 2026? - Management refrained from providing specific guidance but expressed optimism about growth in both China and ex-China markets [44] Question: How is the company addressing inventory management in China? - Improved processes and weekly oversight of inventory levels have been implemented to prevent future buildups [47] Question: What is the strategy for U.S. growth versus China growth? - Management emphasized that while China remains the largest opportunity, the U.S. business is also seeing success and will continue to be a focus [53]

Financial Data and Key Metrics Changes - Total net sales for Q4 2025 were $57.8 million, compared to $49 million in the same quarter last year, driven by a lower than expected rebound in sales in China, partially offset by growth in the Americas and non-China APAC regions [21] - Gross profit margin for Q4 2025 was 75.7%, up from 64.7% in the prior year quarter, primarily due to the timing of cost recognition and cost reductions implemented earlier [22] - Adjusted EBITDA for Q4 2025 was a loss of $200,000, an improvement from a loss of $20.8 million in the year-ago quarter, attributed to higher gross profit and lower operating expenses [24] Business Line Data and Key Metrics Changes - China net sales in Q4 2025 were $17.5 million, up from $7.8 million in the year-ago quarter, although certain sub-distributors returned inventory, impacting sales [21] - Excluding China, net sales declined by 2% year-over-year, with the Americas up 18%, EMEA down 20%, and APAC ex-China up 2% in Q4 [22] Market Data and Key Metrics Changes - In China, demand for EVO ICL recovered at mid-single digit rates, but did not translate into net sales growth due to inventory reductions by distributors [10] - The U.S. business showed momentum despite a decline in laser vision correction procedures, with an expanded age range indication for EVO increasing the potential candidate pool by approximately 8 million [11] Company Strategy and Development Direction - The company aims for growth, improving profitability, and progress in its innovation pipeline for 2026, following a challenging 2025 [8] - Focus on enterprise-wide impacts and disciplined investing to drive profitability, including manufacturing improvements and optimizing average selling prices (ASPs) [13] - The company is advancing its ERP implementation and launching new products like EVO+ in China, which is expected to enhance margins and ASPs [14][15] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the recovery in China and the potential for growth in 2026, despite previous challenges [10] - The leadership team emphasized the importance of maintaining cost discipline while targeting profitability in FY 2026 [25] - Management acknowledged the need for continued innovation and the introduction of new products to capture market share [85] Other Important Information - The company has no debt and ended Q4 2025 with approximately $187.5 million in cash equivalents and investments [25] - The leadership structure has transitioned to a shared role of Interim Co-CEOs, aiming for continuity and alignment in strategy execution [6][8] Q&A Session Summary Question: Have the reductions in distributor inventory continued into Q1 or stabilized now that Alcon is behind? - Management reported stable inventory levels at distributors, slightly below the six-month contractual level, indicating readiness for market recovery [32] Question: How does the health of the organization today compare to pre-Alcon? - Management noted improved cost control and alignment within the organization post-Alcon, focusing on growth and profitability [36] Question: What is the expected growth for 2026 collectively? - Management refrained from providing specific guidance but expressed optimism about growth in both China and ex-China markets [44] Question: What structural changes have been implemented to prevent inventory buildups in China? - Enhanced processes for inventory management have been established, allowing for better visibility and control over distributor inventory levels [48] Question: How should we think about prioritization between U.S. growth and China growth? - Management emphasized that while the U.S. business is growing, China remains the largest opportunity, and investments will continue in both markets [53] Question: What is the growth algorithm moving forward? - Management indicated that while they do not expect to return to hyper-growth levels, they are working towards significant growth opportunities in 2026 [57]

Financial Data and Key Metrics Changes - The company achieved sales of approximately $168 million for Q1 2025, with organic sales up 2.8% compared to the previous year [10] - Adjusted diluted earnings per share were $0.26, and adjusted EBITDA was approximately $22 million, with adjusted gross margins at 56.7% [10] - The balance sheet remains strong with $97 million in cash and $107 million in debt outstanding as of March 31 [10] Business Line Data and Key Metrics Changes - Specialty Nutrition Systems segment grew almost 9% organically compared to the prior year, reaffirming its number one position in long-term, short-term, and neonatal internal feeding [14] - Pain Management and Recovery segment saw normalized organic sales up 2.4%, with near double-digit growth in the radiofrequency ablation business [16][17] - Operating profit for the Specialty Nutrition Systems segment was nearly 21%, a 460 basis point increase from the prior year [15] Market Data and Key Metrics Changes - The company anticipates a softer Q2 for the Specialty Nutrition Systems segment due to distributor order timing but remains confident in the segment's strength for the rest of the year [19] - The company incurred $1.5 million in tariffs during Q1, with an estimated $15 million in incremental tariff-related manufacturing costs for the year [21][22] Company Strategy and Development Direction - The company is focused on enhancing its growth profile through transformation efforts, capital deployment for M&A, and partnerships [7][11] - The organizational focus has been refined to ensure clarity in strategic business priorities for 2025, aiming for margin expansion and improved patient and customer experience [11][12] - The company plans to transition all syringe manufacturing and supply chain operations out of China by the first half of 2026 in response to tariffs [19] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the strong start to the year, particularly in strategic segments, while acknowledging the dynamic economic environment [23] - The revised adjusted EPS estimate reflects a reasonable view of the tariff impact on full-year results, with ongoing monitoring of the situation [23] Other Important Information - The company has closed two smaller transactions this year that support its specialty nutrition system strategy [11] - The new operating segments are expected to provide improved visibility and highlight the financial profiles of the two segments [13] Q&A Session Summary Question: How does the company view the second quarter relative to the first? - Management indicated that while the second quarter may see a slight decline due to distributor order dynamics, they maintain confidence in the full-year guidance [30][31] Question: Can you elaborate on the tariff assumptions and their impact? - Management expects approximately $15 million in incremental tariff-related manufacturing costs for the year, with strategies in place to mitigate these impacts [41][44] Question: What are the growth expectations for the segments moving forward? - Management anticipates mid-single-digit growth for the Specialty Nutrition Systems segment and flat to low single-digit growth for the Pain Management and Recovery segment for the year [51][53]

Financial Data and Key Metrics Changes - Total sales for Q1 2025 were $321.3 million, representing a year-over-year increase of 2.9% as reported and 3.8% in constant currency, slightly better than guidance [7] - Adjusted net income for Q1 was $29.6 million, an increase of 19.6% year-over-year, with adjusted diluted net earnings per share of $0.95, up 20.1% year-over-year [21] - Adjusted gross margin for Q1 was 56.4%, which is 80 basis points higher than the prior year quarter [18] Business Line Data and Key Metrics Changes - Constant currency sales growth in orthopedics was 3.9%, with double-digit growth in foot and ankle products [7] - General surgery sales saw constant currency growth of 3.8%, driven by strong demand for AirSeal and smoke evacuation products [9] - U.S. orthopedic sales decreased by 2.1%, while international orthopedic sales increased by 7.9% [16] Market Data and Key Metrics Changes - U.S. general surgery sales grew by 6.9%, while international general surgery sales decreased by 3.3% due to declines in energy and critical care product lines [16] - The company noted strong demand for its products, particularly in minimally invasive surgery and areas of laparoscopy and arthroscopy [12] Company Strategy and Development Direction - The company is focused on improving supply chain operations and expects to see significant savings from these initiatives, with a target of at least $20 million in annual savings [18] - Management emphasized the importance of clinical differentiation in products like BioBrace and AirSeal, which are expected to drive future growth [8][12] - The company is working on enhancing its supply chain stability and continuity to support future growth [45] Management's Comments on Operating Environment and Future Outlook - Management acknowledged uncertainties in the macroeconomic environment but noted strong demand for their products [11] - The company remains optimistic about its growth drivers and is focused on operational improvements to enhance performance [27] - Management expects revenue growth for the year to be between 4% and 6% in constant currency, with an improved outlook due to currency effects [23][30] Other Important Information - The company received FDA clearance for a new delivery device for rotator cuff repair, which is expected to enhance surgical procedures [8] - Cash flow from operations for Q1 was $41.5 million, compared to $29.1 million in the same quarter of the previous year [22] Q&A Session Summary Question: Guidance and hospital budgets - Management indicated no concerns about softness in hospital budgets and maintained guidance for the year [30] Question: CEO's perspective on surprises - The CEO noted no negative surprises but was positively surprised by the commitment of the ConMed team and customer embrace of their technology [34] Question: Tariff impact and mitigation efforts - Management discussed the impact of tariffs, particularly from China, and outlined mitigation strategies including logistics adjustments and potential price changes [40][42] Question: Supply chain improvement initiatives - Management provided updates on supply chain improvements, focusing on procurement, planning, and production, with positive progress noted in key portfolios [45][49] Question: Growth potential post-supply chain issues - Management expressed confidence in achieving higher growth rates once supply chain issues are resolved, targeting a balanced mix of growth drivers [72][74]

Financial Data and Key Metrics Changes - The company achieved 11% organic revenue growth in 2024, marking the second consecutive year of double-digit organic growth [5][10] - Adjusted operating income grew by 41%, and adjusted diluted earnings per share increased by 21% [11] - Free cash flow for the full year 2024 was $163 million, representing a 70% increase from the prior year [34] Business Line Data and Key Metrics Changes - Cardiopulmonary segment revenue for Q4 was $182 million, an 11% increase year-over-year, with full-year revenue of $684 million, growing 14% [11][13] - Epilepsy revenue increased by 1% in Q4, with U.S. epilepsy revenue growing by 4% year-over-year [15][16] - The company expects cardiopulmonary revenue to grow by 7% to 8% in 2025 and global epilepsy revenue to grow by 4% to 5% [13][17] Market Data and Key Metrics Changes - The hypoglossal nerve stimulation market for obstructive sleep apnea is expected to approach $2 billion by the end of the decade [7] - The company noted a growing worldwide prevalence of obstructive sleep apnea, with significant unmet needs in the market [60] Company Strategy and Development Direction - The company is focusing on innovation and growth, with a clear strategy to enhance its talent and culture [8][40] - Investment will be increased to accelerate product development in obstructive sleep apnea and difficult-to-treat depression [7][26] - The company aims to leverage its clinical and scientific expertise to expand into new therapeutic areas [6][8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to continue delivering strong financial results and achieving significant milestones in innovation [5][40] - The company is optimistic about the future growth potential in both core and new markets, driven by strong clinical data and market demand [60][100] Other Important Information - The company plans to submit a PMA for obstructive sleep apnea in the first half of 2025, with a limited commercial launch expected thereafter [63] - Adjusted free cash flow is projected to be between $135 million and $155 million for 2025, reflecting increased capital spending [36] Q&A Session Summary Question: Can you help us understand the U.S. and EU cardiopulmonary performance in the quarter? - Management acknowledged a challenging comparison due to previous high growth but noted sequential growth in HLM placements and strong demand for consumables [46] Question: What is the impact of the launch of the new ECMO related product? - Management highlighted that innovation is a key focus and expects the new product to drive growth in 2025 [50][57] Question: How much are you spending to prepare for the sleep apnea launch? - The company invested $27 million in 2024 and plans to invest an additional $8 million in 2025, shifting focus from clinical spend to product development [61] Question: What are the execution issues in the OUS epilepsy business? - Management identified personnel issues as isolated across different markets and expressed confidence in returning to growth [66] Question: Can you provide insight into revenue phasing for 2025? - Management indicated that Q1 is typically the lowest quarter, with growth expected to ramp up throughout the year [69] Question: What is the expected impact of the Siena ruling? - Management stated that they do not anticipate a decision at the upcoming hearing but expect a ruling in the first half of 2025 [78] Question: How does the company view capital allocation between core business and new initiatives? - Management emphasized the importance of sustaining growth in core businesses while also investing in new growth opportunities [100]